Mi az ára DelMar Pharmaceuticals, Inc. (DMPWW)

DelMar Pharmaceuticals, Inc. (DMPWW) ára $0.005

Mi a DelMar Pharmaceuticals, Inc. (DMPWW piaci tőkésítése)

DelMar Pharmaceuticals, Inc. piaci tőkésítése (DMPWW) $1.74K

DelMar Pharmaceuticals, Inc. (DMPWW) Ár és Piaci Kapitalizáció

Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.

A DMPWW ára	B aktíva	A B piaci tőkésítése	Eredmények
$15,600,408 $1.74K	NVDA	$5.426T	+312,008,150,437.63%
$12,725,073 $1.74K	AAPL	$4.426T	+254,501,450,684.89%
$11,956,561 $1.74K	GOOG	$4.159T	+239,131,220,200.79%
$10,530,097 $1.74K	MSFT	$3.663T	+210,601,936,648.89%
$8,314,315 $1.74K	AMZN	$2.892T	+166,286,290,888.50%

A DMPWW ára

B aktíva

A B piaci tőkésítése

Eredmények

$15,600,408 $1.74K